Announcements Trials

Browse Landscape

Phase

Phase EARLY_PHASE1 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 2 Lymphoid 2 Thoracic 1 Sarcoma 1 Plasma cell 1 Head & Neck 1 Gastrointestinal 1 Dermatologic 1 CNS 1

Conditions

Interventions

pembrolizumab 100 Nivolumab 69 Cyclophosphamide 67 Ipilimumab 66 fludarabine 34 aldesleukin 29 fludarabine phosphate 28 Vemurafenib 28 Interleukin-2 26 trametinib 20 Biopsy 20 dabrafenib 17 Radiotherapy 16 Temozolomide 15 Cisplatin 15 Magnetic Resonance Spectroscopy 14 Gemcitabine 14 Filgrastim 14 atezolizumab 13 Carboplatin 13 CTLA-4 Antigen 13 spartalizumab 12 romidepsin 12 Specimen Handling 12 Paclitaxel 12 Bortezomib 11 poly ICLC 10 cobimetinib 10 Peripheral Blood Stem Cell Transplantation 10 Oxaliplatin 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × urelumab × Dermatologic × Clear all

NCT00803374 2011-11-21

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

Bristol-Myers Squibb

Phase 1 Withdrawn

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡